AARDEX Group

Meet the team behind the MEMS system at ESPACOMP 2017

CDER-Drug-Packaging
OCT-2017 : Want to meet the team behind MEMS®, the original Smart Packages

OCT-2017 : Want to meet the team behind MEMS®, the original Smart Packages, and electronic adherence of patient monitoring? Meet us at Espacomp 2017!

ESPACOMP in short

  • 3 days dedicated to patient adherence
  • 2 workshops
  • Over 40 individual sessions
  • 32 Speakers


About ESPACOMP
Purpose: ESPACOMP is a non-profit association established to promote the science concerned with the quantitative assessment of what patients do with medicines they have been prescribed. Both the reasons for, and the clinical and economic consequences of, differences between caregivers’ prescriptions and patients’ execution of those prescriptions are principal topics of research with which the Society is concerned, along with facilitation of the translation of this research into information that is useful to patients, healthcare providers, healthcare policy makers, and pharmaceutical researchers.

Origin: Since 1996, a group of scientists from Belgium and the Netherlands organized the « Lowlands » symposium to share their research on patient compliance and persistence with prescribed therapy. This symposium has grown over the years reflecting the increased interest for adherence related issues across Europe. In order to reflect the international expansion of the symposium, in 2006, the organizing committee decided to rename the symposium as “European Symposium on Patient Adherence Compliance and Persistence” and to extend it to other European countries. In 2009, The European Society for Patient Adherence, Compliance, and Persistence was founded.

Annual Meeting: Today, the principal activity of ESPACOMP is to organize a yearly symposium. It has become the meeting place for an increasing number of international adherence researchers, pharmacoepidemiologists, statisticians and industry people interested in compliance and persistence. The next meeting will be held in Budapest, HUNGARY on November 30, 2017.

Share This Post

You may also like...

Breaking News

Dose reduction’s role in tackling Pharma 2.0’s profitability problem

The economic model that has underpinned the development of drug products for decades is currently under siege. Faced on one side with mounting pressure from payers to address affordability issues, pharmaceutical companies are facing ever more stringent regulatory requirements alongside